NPPB and amyloidosis: When the study groups are ordered control > T2D > HFpEF > amyloid, there was a stepwise increase in the severity of conventional HFpEF markers (Figure 1C), including symptom burden (New York Heart Association status; P<0.001), HFA-PEFF score (from 0 [0, 1] to 6 [5.5, 6]; P<0.001), serum NT-proBNP level (from 78 [49, 91] to 4217 pg/mL [1964, 9978]; P<0.001), diastolic dysfunction (E/e′ ratio from 6.9 [5.4, 8.0] to 19.3 [13.5, 21.6]; P<0.001), and estimated sPAPs (sPAP from 9.1 [7.8, 10.8] to 40.7 mm Hg [22.5, 53.5]; P<0.001).